



Contact:

Carol Sexton  
Nucleonics, Inc.  
267-518-0100  
info@nucleonicsinc.com

Joan Kureczka  
Kureczka/Martin Associates  
415-821-2413  
jkureczka@comcast.net

**FOR IMMEDIATE RELEASE**

### **NUCLEONICS NAMES CLINICAL ADVISORY BOARD**

**HORSHAM, PA (September 23, 2004):** Nucleonics, Inc., a biotechnology company focused on the development of novel RNA interference-based (RNAi) therapeutics, today announced the establishment of the company's clinical advisory board.

"Each of these individuals are internationally recognized authorities in the fields of Hepatitis B and C infection, immunology, or cancer, whose experience directly relates to Nucleonics' focus on developing RNA interference-based therapies for viral and other diseases," said Robert J. Towarnicki, Nucleonics president and chief executive officer.

The members of the Nucleonics' clinical advisory board include:

- Francis V. Chisari, M.D. -- Professor of Virology and head of the Division of Experimental Pathology, Scripps Research Institute (La Jolla, CA). Dr. Chisari is well known for his work on Hepatitis B and C virus infections and carcinogenesis. He is widely recognized for a series of discoveries that defined the immunological basis for HBV clearance, persistence and pathogenesis, and for establishing the rationale for the development of therapeutic immunization for these chronic infections. Recently, he and his colleagues have used RNA interference to suppress the replication of these viruses in cell culture and in experimental animals. He has written over 300 papers on these subjects and has received numerous honors and awards for his work, including election to the National Academy of Sciences and the Institute of Medicine.
- Jules L. Dienstag, M.D. – Associate Professor of Medicine, Harvard Medical School and Executive Director, Liver, Biliary and Pancreas Center at Massachusetts General Hospital. As a hepatologist, clinical investigator, and teacher, Dr. Dienstag has devoted his career to understanding, prevention, and management of viral hepatitis, and the evaluation of novel antiviral agents for the treatment of Hepatitis B and Hepatitis C.

-- More --

## **Nucleonics Names Clinical Advisory Board**

### **Page 2**

- W. Thomas London, M.D. -- Director of the Liver Cancer Prevention Center and a senior member at the Fox Chase Cancer Center (Philadelphia). He received the Distinguished Scientist Award in 1998 from the Hepatitis B Foundation and the Distinguished Interdisciplinary Research Award in 1999 from the American Cancer Society, Southeast Region.
- John G. McHutchison, M.D. -- Medical Director, Gastroenterology & Hepatology Research, Duke Clinical Research Institute, Duke University. He is a Fellow of the Royal Australian College of Physicians and is a member of several professional organizations including the American Association for the Study of Liver Diseases and the American Gastroenterology Association. Dr. McHutchison has published worldwide in the field of liver diseases, and is the author of numerous articles and book chapters on chronic hepatitis C infection. In addition to his broad clinical research activities, he has played a lead role in many key HCV drug development programs and clinical trials.
- Robert P. Perrillo, M.D. -- Director of Academic Affairs, Section of Gastroenterology & Hepatology, Ochsner Clinic Foundation (New Orleans). Dr. Perrillo is an internationally recognized clinical investigator in the areas of antiviral therapy and epidemiology. He is best known for his contributions as a key clinical investigator in the areas of alpha interferon treatment of chronic hepatitis and has been a major contributor to the medical literature on the use of nucleoside analogue therapy in patients with advanced hepatitis B.

Nucleonics, founded in January 2001, is an emerging biotechnology company focused on the development of novel RNA interference-based therapeutics for viral and other diseases. Nucleonics is headquartered in Horsham, Pennsylvania and is privately owned.

###